Department of Orthopaedic Surgery, University Hospital Muenster, Muenster, Germany.
J Surg Oncol. 2011 Mar 1;103(3):269-75. doi: 10.1002/jso.21820. Epub 2010 Dec 29.
One of the most difficult problems in tumor surgery is the treatment of pelvic tumors, particularly those in the periacetabular region. This retrospective study serves to analyze clinical and functional outcome of the new surgical technique of hip transposition.
Sixty-two patients were analyzed (chondrosarcoma 15, Ewing's sarcoma or PNET 26, osteosarcoma 14, synovial cell sarcoma 2, others 5) and clinical, oncological, and functional outcome were evaluated.
The surgical procedure focused on hip transpositions Type I (n = 9), Type IIa using the MUTARS attachment tube (n = 36), and Type IIb using the MUTARS attachment tube with a proximal femur endoprosthesis and bipolar cup (n = 17). In 53 patients (85.5%), wide margins were achieved. The 1- and 5-year overall survival rates were 96.4% and 80.5%, respectively. The 5-year (10 years) overall survival was 82.1% (82.1%) for Ewing's sarcoma, 60.1% (40.6%) for osteosarcoma, and 92.3% (46.2%) for chondrosarcoma. Wound healing problems were observed in 14 cases, deep infection in 20 cases. The mean Musculoskeletal Tumor Society (MSTS) score was 62% (18.6 Pts ± 3.73).
Hip transposition can be considered as an easy and safe surgical procedure to employ in order to achieve good functional outcome in periacetabular tumors.
肿瘤外科中最困难的问题之一是骨盆肿瘤的治疗，尤其是髋臼周围区域的肿瘤。本回顾性研究旨在分析髋关节移位新手术技术的临床和功能结果。
分析了 62 例患者（软骨肉瘤 15 例，尤文肉瘤或 PNET 26 例，骨肉瘤 14 例，滑膜细胞肉瘤 2 例，其他 5 例），评估了临床、肿瘤学和功能结果。
手术重点是髋关节移位Ⅰ型（n=9）、MUTARS 附件管Ⅱa 型（n=36）和 MUTARS 附件管联合股骨近端假体和双极杯Ⅱb 型（n=17）。在 53 例患者（85.5%）中，获得了广泛的切缘。1 年和 5 年总生存率分别为 96.4%和 80.5%。Ewing 肉瘤的 5 年（10 年）总生存率为 82.1%（82.1%），骨肉瘤为 60.1%（40.6%），软骨肉瘤为 92.3%（46.2%）。14 例出现伤口愈合问题，20 例出现深部感染。肌肉骨骼肿瘤学会（MSTS）评分平均为 62%（18.6 分±3.73）。
髋关节移位术可作为一种简单、安全的手术方法，用于获得髋臼周围肿瘤的良好功能结果。
